• Hansa Biopharma presented positive results from its European Idefirix post-authorization study at ASN Kidney Week 2026.
• Idefirix enabled kidney transplants in highly sensitized patients, with most recipients alive with functioning transplants one year later.
• Treatment was generally well tolerated, with no new safety signals; antibody-mediated rejection caused no graft losses.
• The study supports efforts to secure full European marketing authorization for Idefirix, which currently holds conditional authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansa Biopharma AB published the original content used to generate this news brief via Cision (Ref. ID: 202610231330BITN____UKPR__SV_20261023-BIT-9150-0) on October 23, 2026, and is solely responsible for the information contained therein.